Oncology Biomarkers: Global Markets
Report Scope:
This study provides a comprehensive analysis of oncology biomarkers on a global basis. It aims to offer a range of information, from detailed market analyses within cancer types to overall industry trends, to quantify and qualify the market for products and services in the oncology biomarkers segment. Current and projected market forecasts during the forecast period (2023 to 2028) are discussed. Figures for 2023 are estimated, except where actual results have been reported.
This report includes forecasts by biomarker type, cancer type, application, and region from 2023 through 2028. The report also includes an analysis of leading and emerging competitors in the current worldwide oncology biomarkers market. The competitive environment is examined with a particular focus on how new products and technologies influence the current standard of care.
Report Includes:
This study provides a comprehensive analysis of oncology biomarkers on a global basis. It aims to offer a range of information, from detailed market analyses within cancer types to overall industry trends, to quantify and qualify the market for products and services in the oncology biomarkers segment. Current and projected market forecasts during the forecast period (2023 to 2028) are discussed. Figures for 2023 are estimated, except where actual results have been reported.
This report includes forecasts by biomarker type, cancer type, application, and region from 2023 through 2028. The report also includes an analysis of leading and emerging competitors in the current worldwide oncology biomarkers market. The competitive environment is examined with a particular focus on how new products and technologies influence the current standard of care.
Report Includes:
- 21 data tables and 60 additional tables
- An in-depth analysis of the global oncology biomarkers market
- Analyses of global market trends, with data from 2020, 2021, 2022, and projections of compound annual growth rates (CAGRs) through 2028
- Characterization and quantification of biomarkers market by type, profiling technology, application, cancer type, and region
- Discussion on market drivers, challenges and key market strategies and trends
- Information on emerging products and technologies, new analytical platforms, novel immunoassays, and bioinformatics tools and discussion on the use of biomarkers in cancer drug development
- Profiles of the competitive landscape with an overview of competitor growth strategies and opportunities
CHAPTER 1 INTRODUCTION
Study Goals and Objectives
Reasons for Doing This Study
Scope of Report
Methodology and Information Sources
Geographic Breakdown
Analyst’s Credentials
BCC Custom Research
Related BCC Research Reports
CHAPTER 2 SUMMARY AND HIGHLIGHTS
CHAPTER 3 MARKET OUTLOOK
CHAPTER 4 MARKET AND TECHNOLOGY BACKGROUND
Overview of Biomarkers
Classification of Biomarkers
Types of Biomarkers
Biomarker Discovery, Verification and Validation
Overview of Cancer
Cancer/Oncology Biomarkers
Oncology Biomarkers Testing Methods
Oncology Biomarkers Testing Types
Biomarker Test Development and Marketing
CHAPTER 5 MARKET DYNAMICS
Drivers
Rising Incidence of Cancer
Increasing Use of Biomarkers in Drug Discovery and Development
Developments in Analytical Technologies and Assay Methods
Increased Availability and Ease of Biomarker Testing
Support from Regulatory Agencies
Barriers
Inadequate Patient Access to and Insurance Coverage of Biomarker Testing
Technical Errors and Delayed Test Results
Low Provider and Patient Awareness
Suboptimal Tissue Procurement and Triaging
Shortages of Laboratories and Personnel
CHAPTER 6 MARKET BREAKDOWN BY BIOMARKER TYPE
Protein Biomarkers
Protein Biomarkers Profiling Technologies
Genomic Biomarker
Genomic Biomarkers Profiling Technologies
Other Biomarkers
Metabolomic Biomarkers
Cellular Biomarkers
Global Market for Oncology Biomarkers, by Biomarker Type
Protein Biomarkers
Genomic Biomarkers
Other Biomarkers
CHAPTER 7 MARKET BREAKDOWN BY APPLICATION
Life Science Research
Risk Assessment and Screening
Diagnostics
Prognostics
Therapeutic Selection and Clinical Trials
Monitoring
Response Monitoring
Recurrence/Minimal Residual Disease (MRD) Monitoring
Global Market for Oncology Biomarkers by Application
Life Science Research
Risk Assessment and Screening
Diagnostics
Prognostics
Therapeutic Selection and Clinical Trials
Monitoring
CHAPTER 8 MARKET BREAKDOWN BY CANCER TYPE
Market Overview
Breast Cancer
Lung Cancer
Colorectal Cancer (CRC)
Prostate Cancer
Bladder Cancer
Melanoma
Leukemia
Others
Ovarian Cancer
Liver Cancer
Thyroid Cancer
Cervical Cancer
Kidney Cancer
Endometrial Cancer
Global Market for Oncology Biomarkers by Cancer Type
Breast Cancer
Lung Cancer
Colorectal Cancer
Prostate Cancer
Bladder Cancer
Melanoma
Leukemia
Other Cancers
CHAPTER 9 MARKET BREAKDOWN BY REGION
Global Market for Oncology Biomarkers by Region
North America
Market Revenue by Application
Market Revenue by Country
Europe
Market Revenue by Application
Market Revenue by Country
Asia-Pacific
Market Revenue by Application
Market Revenue by Country
Rest of World
Market Revenue by Application
CHAPTER 10 IMPACT OF COVID-19
Overview
Implications on Cancer Diagnosis
Implications on Cancer Treatment
Impact on Oncology Biomarkers Market
CHAPTER 11 EMERGING TRENDS AND TECHNOLOGIES IN THE MARKET
Emerging Technologies and Trends in the Market
Liquid Biopsy
Circulating Free Nucleic Acids
Circulating Cell-Free DNA (CfDNA)
“Organ Agnostic” Biomarker Testing
PD-L1
Homologous Recombination De?ciency (HRD)
Blood Test for Early-Stage Cancer Detection
CHAPTER 12 COMPETITIVE LANDSCAPE
Overview
Mergers and Acquisitions
SWOT Analysis for Global Oncology Biomarker Market
Porter’s Five Forces Analysis of Global Oncology Biomarker Market
CHAPTER 13 COMPANY PROFILES
AGENDIA INC.
ABBOTT
AGILENT TECHNOLOGIES INC.
BIOCARTIS NV
BIOMERIEUX S.A.
BIO-RAD LABORATORIES INC.
BECTON, DICKINSON & CO.
EXACT SCIENCES CORP.
F. HOFFMANN-LA ROCHE AG
GUARDANT HEALTH INC.
HOLOGIC INC.
ILLUMINA INC.
LEICA BIOSYSTEMS
MERCK KGAA
MYRIAD GENETICS INC.
QIAGEN N.V.
SIEMENS HEALTHINEERS AG
THERMO FISHER SCIENTIFIC INC.
VERACYTE INC.
CHAPTER 14 APPENDIX: ACRONYMS
Study Goals and Objectives
Reasons for Doing This Study
Scope of Report
Methodology and Information Sources
Geographic Breakdown
Analyst’s Credentials
BCC Custom Research
Related BCC Research Reports
CHAPTER 2 SUMMARY AND HIGHLIGHTS
CHAPTER 3 MARKET OUTLOOK
CHAPTER 4 MARKET AND TECHNOLOGY BACKGROUND
Overview of Biomarkers
Classification of Biomarkers
Types of Biomarkers
Biomarker Discovery, Verification and Validation
Overview of Cancer
Cancer/Oncology Biomarkers
Oncology Biomarkers Testing Methods
Oncology Biomarkers Testing Types
Biomarker Test Development and Marketing
CHAPTER 5 MARKET DYNAMICS
Drivers
Rising Incidence of Cancer
Increasing Use of Biomarkers in Drug Discovery and Development
Developments in Analytical Technologies and Assay Methods
Increased Availability and Ease of Biomarker Testing
Support from Regulatory Agencies
Barriers
Inadequate Patient Access to and Insurance Coverage of Biomarker Testing
Technical Errors and Delayed Test Results
Low Provider and Patient Awareness
Suboptimal Tissue Procurement and Triaging
Shortages of Laboratories and Personnel
CHAPTER 6 MARKET BREAKDOWN BY BIOMARKER TYPE
Protein Biomarkers
Protein Biomarkers Profiling Technologies
Genomic Biomarker
Genomic Biomarkers Profiling Technologies
Other Biomarkers
Metabolomic Biomarkers
Cellular Biomarkers
Global Market for Oncology Biomarkers, by Biomarker Type
Protein Biomarkers
Genomic Biomarkers
Other Biomarkers
CHAPTER 7 MARKET BREAKDOWN BY APPLICATION
Life Science Research
Risk Assessment and Screening
Diagnostics
Prognostics
Therapeutic Selection and Clinical Trials
Monitoring
Response Monitoring
Recurrence/Minimal Residual Disease (MRD) Monitoring
Global Market for Oncology Biomarkers by Application
Life Science Research
Risk Assessment and Screening
Diagnostics
Prognostics
Therapeutic Selection and Clinical Trials
Monitoring
CHAPTER 8 MARKET BREAKDOWN BY CANCER TYPE
Market Overview
Breast Cancer
Lung Cancer
Colorectal Cancer (CRC)
Prostate Cancer
Bladder Cancer
Melanoma
Leukemia
Others
Ovarian Cancer
Liver Cancer
Thyroid Cancer
Cervical Cancer
Kidney Cancer
Endometrial Cancer
Global Market for Oncology Biomarkers by Cancer Type
Breast Cancer
Lung Cancer
Colorectal Cancer
Prostate Cancer
Bladder Cancer
Melanoma
Leukemia
Other Cancers
CHAPTER 9 MARKET BREAKDOWN BY REGION
Global Market for Oncology Biomarkers by Region
North America
Market Revenue by Application
Market Revenue by Country
Europe
Market Revenue by Application
Market Revenue by Country
Asia-Pacific
Market Revenue by Application
Market Revenue by Country
Rest of World
Market Revenue by Application
CHAPTER 10 IMPACT OF COVID-19
Overview
Implications on Cancer Diagnosis
Implications on Cancer Treatment
Impact on Oncology Biomarkers Market
CHAPTER 11 EMERGING TRENDS AND TECHNOLOGIES IN THE MARKET
Emerging Technologies and Trends in the Market
Liquid Biopsy
Circulating Free Nucleic Acids
Circulating Cell-Free DNA (CfDNA)
“Organ Agnostic” Biomarker Testing
PD-L1
Homologous Recombination De?ciency (HRD)
Blood Test for Early-Stage Cancer Detection
CHAPTER 12 COMPETITIVE LANDSCAPE
Overview
Mergers and Acquisitions
SWOT Analysis for Global Oncology Biomarker Market
Porter’s Five Forces Analysis of Global Oncology Biomarker Market
CHAPTER 13 COMPANY PROFILES
AGENDIA INC.
ABBOTT
AGILENT TECHNOLOGIES INC.
BIOCARTIS NV
BIOMERIEUX S.A.
BIO-RAD LABORATORIES INC.
BECTON, DICKINSON & CO.
EXACT SCIENCES CORP.
F. HOFFMANN-LA ROCHE AG
GUARDANT HEALTH INC.
HOLOGIC INC.
ILLUMINA INC.
LEICA BIOSYSTEMS
MERCK KGAA
MYRIAD GENETICS INC.
QIAGEN N.V.
SIEMENS HEALTHINEERS AG
THERMO FISHER SCIENTIFIC INC.
VERACYTE INC.
CHAPTER 14 APPENDIX: ACRONYMS
LIST OF TABLES
Summary Table: Global Market for Oncology Biomarkers, by Biomarker Type, Through 2028
Table 1: Different Categories of Biomarkers
Table 2: Multiple Paths to Market for Biomarker Test
Table 3: Biomarkers: Drug Development
Table 4: FDA Issued Letters of Support to Cancer Biomarkers
Table 5: Three Biggest Barriers to Biomarker Testing
Table 6: Selected Protein Biomarkers Used in Oncology
Table 7: Examples of Genomic Biomarkers
Table 8: NGS Methods Used in Oncology
Table 9: PMA Approved NGS Oncology Panel, Somatic or Germline Variant Detection System
Table 10: Selected Genomic Biomarkers Used in Oncology
Table 11: Potential Applications of CTC-Based Diagnostics
Table 12: Global Market for Oncology Biomarkers, by Biomarker Type, Through 2028
Table 13: FDA Novel Drug Approvals with Predictive Biomarkers, Jan. 2021–Jan. 2023
Table 14: Total Number of Biomarkers Used in FDA Approved Therapeutic Selection Tests or CDx, by Cancer Type, 2022
Table 15: Global Market for Oncology Biomarkers, by Application, Through 2028
Table 16: NIH Funding for Cancer Research, by Cancer Type, Through 2024
Table 17: Total Number of Drugs with Approved CDx, by Cancer Type, 2021
Table 18: Estimated Numbers for All Cancers Excl. Non-Melanoma Skin Cancer in 2020
Table 19: Selected Key Biomarkers for Breast Cancer
Table 20: Biomarkers Used in Breast Cancer Therapy Selection
Table 21: Selected Key Biomarkers for Lung Cancer
Table 22: Biomarkers Used in Lung Cancer Therapy Selection
Table 23: Selected CRC Screening Products/Tests
Table 24: Selected Key Biomarkers for CRC
Table 25: Biomarkers Used in CRC Therapy Selection
Table 26: Selected Prostate Cancer Screening Tests
Table 27: Biomarkers Used in Prostrate Cancer Therapy Selection
Table 28: Selected Key Biomarkers for Prostate Cancer
Table 29: Selected Key Biomarkers for Bladder Cancer
Table 30: Biomarkers Used in Bladder Cancer Therapy Selection
Table 31: Selected Key Biomarkers for Melanoma
Table 32: Biomarkers Used in Melanoma Therapy Selection
Table 33: Selected Key Biomarkers for Leukemia
Table 34: Biomarkers Used in Leukemia Therapy Selection
Table 35: Selected Key Biomarkers for Ovarian Cancer
Table 36: Biomarkers Used in Ovarian Cancer Therapy Selection
Table 37: Global Market for Oncology Biomarkers, by Cancer Type, Through 2028
Table 38: Global Market for Breast Cancer Biomarkers, by Biomarker Type, Through 2028
Table 39: Global Market for Lung Biomarkers, by Biomarker Type, Through 2028
Table 40: Global Market for Colorectal Cancer Biomarkers, by Biomarker Type, Through 2028
Table 41: Global Market for Prostate Cancer Biomarkers, by Biomarker Type, Through 2028
Table 42: Global Market for Bladder Cancer Biomarkers, by Biomarker Type, Through 2028
Table 43: Global Market for Melanoma Biomarkers, by Biomarker Type, Through 2028
Table 44: Global Market for Leukemia Biomarkers, by Biomarker Type, Through 2028
Table 45: Global Market for Other Cancers Biomarkers, by Biomarker Type, Through 2028
Table 46: Global Market for Oncology Biomarkers, by Region, Through 2028
Table 47: Estimated Numbers of New Cases and Deaths for Common Cancer Type in the U.S. in 2023
Table 48: North American Market for Oncology Biomarkers, by Application, Through 2028
Table 49: North American Market for Oncology Biomarkers, by Country, Through 2028
Table 50: Challenges to Biomarker Testing in Europe
Table 51: Demographic, Cancer and Healthcare Statistics for Selected European Countries
Table 52: Estimated Cancer Incidence and Mortality, Age Standardized Rate in the EU Countries, by Cancer Type, 2020
Table 53: European Market for Oncology Biomarkers, by Application, Through 2028
Table 54: European Market for Oncology Biomarkers, by Country, Through 2028
Table 55: Oncology Statistics in Select Asia-Pacific Countries, 2020
Table 56: Estimated Cancer Cases in Asia-Pacific Countries, by Notable Cancer Types, 2020
Table 57: Asia-Pacific Market for Oncology Biomarkers, by Application, Through 2028
Table 58: Asia-Pacific Market for Oncology Biomarkers, by Country, Through 2028
Table 59: Cancer Statistics, South America and Africa, 2020
Table 60: RoW Market for Oncology Biomarkers, by Application, Through 2028
Table 61: Selected CfDNA-Based Cancer Tests
Table 62: Leading Market Players in Oncology Biomarkers Market, 2022
Table 63: Recent Mergers and Acquisitions in Oncology Biomarkers Market, 2020-2022
Table 64: Porter’s Five Forces Analysis: Global Oncology Biomarkers Market
Table 65: Agilent Technologies Inc.: Selected Key Developments, January 2021-March 2023
Table 66: Biocartis: Selected Key Developments, January 2020-March 2023
Table 67: Bio-Rad Laboratories: Selected Key Developments, January 2020-March 2023
Table 68: BD: Business Segments
Table 69: BD: Selected Key Developments, January 2020-March 2023
Table 70: Exact Sciences Corp.: Key Developments, January 2021 to December 2022
Table 71: Roche: Selected Recent Developments, January 2021 to March 2023
Table 72: Guardant Health: Key Developments, 2021-2022
Table 73: Hologic Inc.: Key Developments, January 2021 to December 2022
Table 74: Illumina Inc: Key Developments, 2021 and 2022
Table 75: Leica Biosystems: Key Developments, January 2021 to December 2022
Table 76: Myriad Genetics: Key Developments, January 2021 to December 2022
Table 77: Qiagen: Key Recent Developments, 2021-April 2023
Table 78: Thermo Fisher Scientific Inc.: Key Developments, January 2021 to January 2023
Table 79: Veracyte: Key Recent Developments, Jan 2021-Jan 2023
Table 80: Abbreviations Used in This Report
Summary Table: Global Market for Oncology Biomarkers, by Biomarker Type, Through 2028
Table 1: Different Categories of Biomarkers
Table 2: Multiple Paths to Market for Biomarker Test
Table 3: Biomarkers: Drug Development
Table 4: FDA Issued Letters of Support to Cancer Biomarkers
Table 5: Three Biggest Barriers to Biomarker Testing
Table 6: Selected Protein Biomarkers Used in Oncology
Table 7: Examples of Genomic Biomarkers
Table 8: NGS Methods Used in Oncology
Table 9: PMA Approved NGS Oncology Panel, Somatic or Germline Variant Detection System
Table 10: Selected Genomic Biomarkers Used in Oncology
Table 11: Potential Applications of CTC-Based Diagnostics
Table 12: Global Market for Oncology Biomarkers, by Biomarker Type, Through 2028
Table 13: FDA Novel Drug Approvals with Predictive Biomarkers, Jan. 2021–Jan. 2023
Table 14: Total Number of Biomarkers Used in FDA Approved Therapeutic Selection Tests or CDx, by Cancer Type, 2022
Table 15: Global Market for Oncology Biomarkers, by Application, Through 2028
Table 16: NIH Funding for Cancer Research, by Cancer Type, Through 2024
Table 17: Total Number of Drugs with Approved CDx, by Cancer Type, 2021
Table 18: Estimated Numbers for All Cancers Excl. Non-Melanoma Skin Cancer in 2020
Table 19: Selected Key Biomarkers for Breast Cancer
Table 20: Biomarkers Used in Breast Cancer Therapy Selection
Table 21: Selected Key Biomarkers for Lung Cancer
Table 22: Biomarkers Used in Lung Cancer Therapy Selection
Table 23: Selected CRC Screening Products/Tests
Table 24: Selected Key Biomarkers for CRC
Table 25: Biomarkers Used in CRC Therapy Selection
Table 26: Selected Prostate Cancer Screening Tests
Table 27: Biomarkers Used in Prostrate Cancer Therapy Selection
Table 28: Selected Key Biomarkers for Prostate Cancer
Table 29: Selected Key Biomarkers for Bladder Cancer
Table 30: Biomarkers Used in Bladder Cancer Therapy Selection
Table 31: Selected Key Biomarkers for Melanoma
Table 32: Biomarkers Used in Melanoma Therapy Selection
Table 33: Selected Key Biomarkers for Leukemia
Table 34: Biomarkers Used in Leukemia Therapy Selection
Table 35: Selected Key Biomarkers for Ovarian Cancer
Table 36: Biomarkers Used in Ovarian Cancer Therapy Selection
Table 37: Global Market for Oncology Biomarkers, by Cancer Type, Through 2028
Table 38: Global Market for Breast Cancer Biomarkers, by Biomarker Type, Through 2028
Table 39: Global Market for Lung Biomarkers, by Biomarker Type, Through 2028
Table 40: Global Market for Colorectal Cancer Biomarkers, by Biomarker Type, Through 2028
Table 41: Global Market for Prostate Cancer Biomarkers, by Biomarker Type, Through 2028
Table 42: Global Market for Bladder Cancer Biomarkers, by Biomarker Type, Through 2028
Table 43: Global Market for Melanoma Biomarkers, by Biomarker Type, Through 2028
Table 44: Global Market for Leukemia Biomarkers, by Biomarker Type, Through 2028
Table 45: Global Market for Other Cancers Biomarkers, by Biomarker Type, Through 2028
Table 46: Global Market for Oncology Biomarkers, by Region, Through 2028
Table 47: Estimated Numbers of New Cases and Deaths for Common Cancer Type in the U.S. in 2023
Table 48: North American Market for Oncology Biomarkers, by Application, Through 2028
Table 49: North American Market for Oncology Biomarkers, by Country, Through 2028
Table 50: Challenges to Biomarker Testing in Europe
Table 51: Demographic, Cancer and Healthcare Statistics for Selected European Countries
Table 52: Estimated Cancer Incidence and Mortality, Age Standardized Rate in the EU Countries, by Cancer Type, 2020
Table 53: European Market for Oncology Biomarkers, by Application, Through 2028
Table 54: European Market for Oncology Biomarkers, by Country, Through 2028
Table 55: Oncology Statistics in Select Asia-Pacific Countries, 2020
Table 56: Estimated Cancer Cases in Asia-Pacific Countries, by Notable Cancer Types, 2020
Table 57: Asia-Pacific Market for Oncology Biomarkers, by Application, Through 2028
Table 58: Asia-Pacific Market for Oncology Biomarkers, by Country, Through 2028
Table 59: Cancer Statistics, South America and Africa, 2020
Table 60: RoW Market for Oncology Biomarkers, by Application, Through 2028
Table 61: Selected CfDNA-Based Cancer Tests
Table 62: Leading Market Players in Oncology Biomarkers Market, 2022
Table 63: Recent Mergers and Acquisitions in Oncology Biomarkers Market, 2020-2022
Table 64: Porter’s Five Forces Analysis: Global Oncology Biomarkers Market
Table 65: Agilent Technologies Inc.: Selected Key Developments, January 2021-March 2023
Table 66: Biocartis: Selected Key Developments, January 2020-March 2023
Table 67: Bio-Rad Laboratories: Selected Key Developments, January 2020-March 2023
Table 68: BD: Business Segments
Table 69: BD: Selected Key Developments, January 2020-March 2023
Table 70: Exact Sciences Corp.: Key Developments, January 2021 to December 2022
Table 71: Roche: Selected Recent Developments, January 2021 to March 2023
Table 72: Guardant Health: Key Developments, 2021-2022
Table 73: Hologic Inc.: Key Developments, January 2021 to December 2022
Table 74: Illumina Inc: Key Developments, 2021 and 2022
Table 75: Leica Biosystems: Key Developments, January 2021 to December 2022
Table 76: Myriad Genetics: Key Developments, January 2021 to December 2022
Table 77: Qiagen: Key Recent Developments, 2021-April 2023
Table 78: Thermo Fisher Scientific Inc.: Key Developments, January 2021 to January 2023
Table 79: Veracyte: Key Recent Developments, Jan 2021-Jan 2023
Table 80: Abbreviations Used in This Report
LIST OF FIGURES
Summary Figure: Global Market for Oncology Biomarkers, by Biomarker Type, 2020-2028
Figure 1: Biomarker Types Categorized by Application and Use in Drug Development and Disease Management
Figure 2: Molecular and Imaging Biomarkers
Figure 3: Biomarker Discovery, Verification and Validation
Figure 4: Cancer Care Spectrum
Figure 5: Types of Biomarker Testing and Their Definitions
Figure 6: Biomarkers in Personalized Treatment
Figure 7: Global Cancer Incidence, by Region, 2020
Figure 8: Global Cancer Incidence, by Region, 2020 vs. 2040
Figure 9: Distribution Shares of R&D Investment in Drug Development, by Function, 2020
Figure 10: Overview of Biomarker Test Benefits for Each Stakeholder
Figure 11: Barriers to the Use of Biomarker Tests Throughout the Patient Journey
Figure 12: Top Barriers to Biomarker Testing in the U.S., 2021
Figure 13: Common Biomarker Testing Methodologies
Figure 14: Four Main Classes of Genomic Alterations
Figure 15: Types of Genomic Biomarkers
Figure 16: Genomic Biomarker Testing Methods
Figure 17: Key Advantages of NGS for Precision Oncology Applications
Figure 18: Evolution of Biomarkers in Clinical Practice
Figure 19: Global Market for Oncology Biomarkers, by Biomarker Type, 2020-2028
Figure 20: Global Market Shares of Oncology Biomarkers, by Biomarker Type, 2022
Figure 21: Hallmark of Cancer
Figure 22: Stages of Cancer
Figure 23: Companion Diagnostics Co-Development Process from Biomarker Discovery to Regulatory Approval
Figure 24: Clinical Applications of Biomarkers in Oncology
Figure 25: Global Market for Oncology Biomarkers, by Application, 2020-2028
Figure 26: Global Market Shares of Oncology Biomarkers, by Application, 2022
Figure 27: Five-Year Overall Survival Rates in the U.S., by Cancer Type
Figure 28: Global Market for Oncology Biomarkers, by Cancer Type, 2020-2028
Figure 29: Global Market Shares of Oncology Biomarkers, by Cancer Type, 2022
Figure 30: Global Market Shares of Breast Cancer Biomarkers, by Biomarker Type, 2022
Figure 31: Global Market Shares of Lung Biomarkers, by Biomarker Type, 2022
Figure 32: Global Market Shares of Colorectal Cancer Biomarkers, by Biomarker Type, 2022
Figure 33: Global Market Shares of Prostate Cancer Biomarkers, by Biomarker Type, 2022
Figure 34: Global Market Shares of Bladder Cancer Biomarkers, by Biomarker Type, 2022
Figure 35: Global Market Shares of Melanoma Biomarkers, by Biomarker Type, 2022
Figure 36: Global Market Shares of Leukemia Biomarkers, by Biomarker Type, 2022
Figure 37: Global Market Shares of Other Cancers Biomarkers, by Biomarker Type, 2022
Figure 38: Global Market for Oncology Biomarkers, by Region, 2020-2028
Figure 39: Global Market Shares of Oncology Biomarkers, by Region, 2022
Figure 40: NIH's Cancer and Cancer Genomics Research Funding, by Year, 2018-2024
Figure 41: North American Market Shares of Oncology Biomarkers, by Application, 2022
Figure 42: European Market Shares of Oncology Biomarkers, by Application, 2022
Figure 43: Asia-Pacific Market Shares of Oncology Biomarkers, by Application, 2022
Figure 44: RoW Market Shares of Oncology Biomarkers, by Application, 2022
Figure 45: Emerging Trends/Technologies in the Oncology Biomarkers Market
Figure 46: Advantages of Liquid Biopsy
Figure 47: PubMed Article Count: “Liquid Biopsy”, 2014-2022
Figure 48: Pan-Cancer Genomic Biomarkers
Figure 49: SWOT Analysis of the Global Oncology Biomarkers Market
Figure 50: Abbott: Diagnostics Revenue, 2020-2022
Figure 51: Abbott: Diagnostics Market Share, by Business Segment, 2022
Figure 52: Agilent Technologies Inc.: Diagnostics and Genomics Revenue, 2020-2022
Figure 53: Biocartis: Annual Net Revenue, 2020-2022
Figure 54: Biocartis: Market Share, by Business Segment, 2022
Figure 55: BioM?rieux SA: Annual Net Revenue, 2020-2022
Figure 56: BioM?rieux SA: Market Share, by Application, 2022
Figure 57: Bio-Rad Laboratories: Annual Net Revenue, 2020-2022
Figure 58: Bio-Rad Laboratories: Market Share, by Business Segment, 2022
Figure 59: BD’s Biosciences Segment: Annual Revenue, 2020-2022
Figure 60: Exact Sciences Corp.: Annual Net Revenue, 2020-2022
Figure 61: Exact Sciences Corp.: Market Share, by Business Segment, 2022
Figure 62: F. Hoffmann-La Roche Ltd.’s Diagnostics Division: Annual Revenue, 2020-2022
Figure 63: F. Hoffmann-La Roche Ltd.’s Diagnostics Division: Market Share, by Customer Area, 2022
Figure 64: Guardant Health: Annual Net Revenue, 2020-2022
Figure 65: Guardant Health: Market Share, by Segment, 2022
Figure 66: Hologic Inc.: Annual Net Revenue, 2020-2022
Figure 67: Hologic Inc.: Market Share, by Business Segment, 2022
Figure 68: Illumina Inc.: Annual Net Revenue, 2020-2022
Figure 69: Illumina Inc.: Market Share, by Business Segment, 2022
Figure 70: Merck KGaA: Annual Revenue, 2020-2022
Figure 71: Merck KGaA: Market Share, by Business Segment, 2022
Figure 72: Myriad Genetics: Annual Net Revenue, 2021 and 2022
Figure 73: Myriad Genetics: Market Share, by Business Segment, 2022
Figure 74: Qiagen: Annual Net Revenue, 2020-2022
Figure 75: Qiagen: Market Share, by Product Type, 2022
Figure 76: Siemens Healthineers AG: Annual Net Revenue, 2020-2022
Figure 77: Siemens Healthineers AG: Market Share, by Business Segment, 2022
Figure 78: Thermo Fisher Scientific Inc.: Annual Revenue, 2020-2022
Figure 79: Thermo Fisher Scientific Inc.: Market Share, by Business Segment, 2022
Figure 80: Veracyte: Annual Revenue, 2020-2022
Figure 81: Veracyte: Market Share, by Business Segment, 2022
Summary Figure: Global Market for Oncology Biomarkers, by Biomarker Type, 2020-2028
Figure 1: Biomarker Types Categorized by Application and Use in Drug Development and Disease Management
Figure 2: Molecular and Imaging Biomarkers
Figure 3: Biomarker Discovery, Verification and Validation
Figure 4: Cancer Care Spectrum
Figure 5: Types of Biomarker Testing and Their Definitions
Figure 6: Biomarkers in Personalized Treatment
Figure 7: Global Cancer Incidence, by Region, 2020
Figure 8: Global Cancer Incidence, by Region, 2020 vs. 2040
Figure 9: Distribution Shares of R&D Investment in Drug Development, by Function, 2020
Figure 10: Overview of Biomarker Test Benefits for Each Stakeholder
Figure 11: Barriers to the Use of Biomarker Tests Throughout the Patient Journey
Figure 12: Top Barriers to Biomarker Testing in the U.S., 2021
Figure 13: Common Biomarker Testing Methodologies
Figure 14: Four Main Classes of Genomic Alterations
Figure 15: Types of Genomic Biomarkers
Figure 16: Genomic Biomarker Testing Methods
Figure 17: Key Advantages of NGS for Precision Oncology Applications
Figure 18: Evolution of Biomarkers in Clinical Practice
Figure 19: Global Market for Oncology Biomarkers, by Biomarker Type, 2020-2028
Figure 20: Global Market Shares of Oncology Biomarkers, by Biomarker Type, 2022
Figure 21: Hallmark of Cancer
Figure 22: Stages of Cancer
Figure 23: Companion Diagnostics Co-Development Process from Biomarker Discovery to Regulatory Approval
Figure 24: Clinical Applications of Biomarkers in Oncology
Figure 25: Global Market for Oncology Biomarkers, by Application, 2020-2028
Figure 26: Global Market Shares of Oncology Biomarkers, by Application, 2022
Figure 27: Five-Year Overall Survival Rates in the U.S., by Cancer Type
Figure 28: Global Market for Oncology Biomarkers, by Cancer Type, 2020-2028
Figure 29: Global Market Shares of Oncology Biomarkers, by Cancer Type, 2022
Figure 30: Global Market Shares of Breast Cancer Biomarkers, by Biomarker Type, 2022
Figure 31: Global Market Shares of Lung Biomarkers, by Biomarker Type, 2022
Figure 32: Global Market Shares of Colorectal Cancer Biomarkers, by Biomarker Type, 2022
Figure 33: Global Market Shares of Prostate Cancer Biomarkers, by Biomarker Type, 2022
Figure 34: Global Market Shares of Bladder Cancer Biomarkers, by Biomarker Type, 2022
Figure 35: Global Market Shares of Melanoma Biomarkers, by Biomarker Type, 2022
Figure 36: Global Market Shares of Leukemia Biomarkers, by Biomarker Type, 2022
Figure 37: Global Market Shares of Other Cancers Biomarkers, by Biomarker Type, 2022
Figure 38: Global Market for Oncology Biomarkers, by Region, 2020-2028
Figure 39: Global Market Shares of Oncology Biomarkers, by Region, 2022
Figure 40: NIH's Cancer and Cancer Genomics Research Funding, by Year, 2018-2024
Figure 41: North American Market Shares of Oncology Biomarkers, by Application, 2022
Figure 42: European Market Shares of Oncology Biomarkers, by Application, 2022
Figure 43: Asia-Pacific Market Shares of Oncology Biomarkers, by Application, 2022
Figure 44: RoW Market Shares of Oncology Biomarkers, by Application, 2022
Figure 45: Emerging Trends/Technologies in the Oncology Biomarkers Market
Figure 46: Advantages of Liquid Biopsy
Figure 47: PubMed Article Count: “Liquid Biopsy”, 2014-2022
Figure 48: Pan-Cancer Genomic Biomarkers
Figure 49: SWOT Analysis of the Global Oncology Biomarkers Market
Figure 50: Abbott: Diagnostics Revenue, 2020-2022
Figure 51: Abbott: Diagnostics Market Share, by Business Segment, 2022
Figure 52: Agilent Technologies Inc.: Diagnostics and Genomics Revenue, 2020-2022
Figure 53: Biocartis: Annual Net Revenue, 2020-2022
Figure 54: Biocartis: Market Share, by Business Segment, 2022
Figure 55: BioM?rieux SA: Annual Net Revenue, 2020-2022
Figure 56: BioM?rieux SA: Market Share, by Application, 2022
Figure 57: Bio-Rad Laboratories: Annual Net Revenue, 2020-2022
Figure 58: Bio-Rad Laboratories: Market Share, by Business Segment, 2022
Figure 59: BD’s Biosciences Segment: Annual Revenue, 2020-2022
Figure 60: Exact Sciences Corp.: Annual Net Revenue, 2020-2022
Figure 61: Exact Sciences Corp.: Market Share, by Business Segment, 2022
Figure 62: F. Hoffmann-La Roche Ltd.’s Diagnostics Division: Annual Revenue, 2020-2022
Figure 63: F. Hoffmann-La Roche Ltd.’s Diagnostics Division: Market Share, by Customer Area, 2022
Figure 64: Guardant Health: Annual Net Revenue, 2020-2022
Figure 65: Guardant Health: Market Share, by Segment, 2022
Figure 66: Hologic Inc.: Annual Net Revenue, 2020-2022
Figure 67: Hologic Inc.: Market Share, by Business Segment, 2022
Figure 68: Illumina Inc.: Annual Net Revenue, 2020-2022
Figure 69: Illumina Inc.: Market Share, by Business Segment, 2022
Figure 70: Merck KGaA: Annual Revenue, 2020-2022
Figure 71: Merck KGaA: Market Share, by Business Segment, 2022
Figure 72: Myriad Genetics: Annual Net Revenue, 2021 and 2022
Figure 73: Myriad Genetics: Market Share, by Business Segment, 2022
Figure 74: Qiagen: Annual Net Revenue, 2020-2022
Figure 75: Qiagen: Market Share, by Product Type, 2022
Figure 76: Siemens Healthineers AG: Annual Net Revenue, 2020-2022
Figure 77: Siemens Healthineers AG: Market Share, by Business Segment, 2022
Figure 78: Thermo Fisher Scientific Inc.: Annual Revenue, 2020-2022
Figure 79: Thermo Fisher Scientific Inc.: Market Share, by Business Segment, 2022
Figure 80: Veracyte: Annual Revenue, 2020-2022
Figure 81: Veracyte: Market Share, by Business Segment, 2022
